U.S., Feb. 5 -- ClinicalTrials.gov registry received information related to the study (NCT06806982) titled 'A Phase 1 Study of VRN101099 in Patients With HER2-Positive Solid Tumors' on Jan. 06.
Brief Summary: This FIH open-label study aims to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and antitumor effect of VRN101099 in patients with HER2-positive solid tumors for whom no standard therapies are available.
Study Start Date: Feb. 11
Study Type: INTERVENTIONAL
Condition:
HER2-positive Solid Tumors
Intervention:
DRUG: VRN101099
Oral capsules
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Voronoi, Inc
Published by HT Digital Content Services with permission from Health Daily Digest....